Related Experiment Video

Updated: Aug 28, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds

Chiara Pallara1, Debora Cabot2,3, Josep Rivas1

  • 1Iproteos S.L., Barcelona Science Park, Baldiri Reixac 10, 08028, Barcelona, Spain.

Scientific Reports
|September 22, 2022
PubMed

Insights

Researchers developed novel peptidomimetics to target oncogenic RAS proteins, crucial drivers of cancer. These compounds effectively inhibit RAS-effector interactions and show promise in reducing pancreatic cancer cell survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Oncogenic RAS proteins are key drivers of tumor formation and maintenance.
  • Targeting RAS-effector interactions presents a significant therapeutic opportunity in cancer treatment.

Purpose of the Study:

  • To identify and develop peptidomimetics that block RAS-effector interactions.
  • To validate computational methods for identifying drug targets on RAS proteins.

Main Methods:

  • Computational analysis to identify RAS 'hot spots' for drug targeting.
  • Screening of a peptidomimetic library against RAS.
  • Synthesis and in vitro testing of nine candidate compounds.
  • Assessing inhibition of ERK and AKT signaling pathways.
  • Evaluating disruption of KRAS-Raf and KRAS-PI3K interactions.

Main Results:

  • Nine peptidomimetics were synthesized and tested for RAS inhibitory activity.
  • Most compounds reduced EGF-induced ERK and AKT activation, indicating RAS pathway inhibition.
  • The most potent inhibitor disrupted oncogenic KRAS interaction with Raf and PI3K.
  • An improved compound demonstrated efficacy in decreasing pancreatic cancer cell line survival.

Conclusions:

  • Computational methodology successfully identified key RAS interaction sites and validated peptidomimetic inhibitors.
  • Disruption of RAS-effector protein-protein interactions is a viable strategy for cancer therapy.
  • Optimized peptidomimetics show potential for treating KRAS-driven pancreatic cancers.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K